Login to Access Video or Poster Abstract: MP26-17
Sources of Funding: none

Introduction

This study aims to express urinary MCP-1 level in OAB patients before and after treatments, and to correlate the level of MCP-1 with severity of symptoms.

Methods

This was a prospective, single-blind study including 26 OAB patients (either newly diagnosed or off medications for 2 weeks). Each patient received after the first visit different OAB treatments (anticholinergic, B3 agonist and or neuromodulations). Two midstream urine samples were collected and tested for MCP-1 using ELISA; one before and the second after 12 weeks of treatments. Symptomatic responses to therapy were evaluated using different validated OAB questionnaires [Patient Perception Bladder Condition (PPBC) & Overactive Bladder Quality (OAB-q)]. MCP-1 level were normalized to the levels of creatinine. Descriptive statistics were performed to examine MCP-1 level before and after different using Wilconxon test. Post-treatment MCP1- levels compared to 12 healthy subjects as control using Mann-Whitney U test.

Results

The mean age of enrolled 26 patients was 69.3yrs. Females accounted for 62.5% of patients. In simple correlation, the degrees of symptoms was significantly associated with the pre-treatment level of MCP-1 (coefficient=.844, p<.000 in PPBC and coefficient=.869, p<.000 in OABq, Figure 1). Mulivariate analysis using linear regression model including age, gender and MCP-1 demonstrated that MCP-1 was significantly associated with OABq (p=.02) and PPBC (p=.03). Twelve weeks after treatment, MCP-1 level was dropped significantly (p<.000), and it was similar with control group (p=0.376, Table). After treatment, the symptom improved significantly both in OAB-q and PPBC (Figure 2).

Conclusions

Based on a strong association with the degree of symptom, urinary MPC-1 can be used to identify patients and monitor the progression of OAB.

Funding

none